GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (STU:NKB2) » Definitions » Ending Cash Position

TG Therapeutics (STU:NKB2) Ending Cash Position : €70.6 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is TG Therapeutics Ending Cash Position?

TG Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was €70.6 Mil.

TG Therapeutics's quarterly Ending Cash Position declined from Sep. 2023 (€142.6 Mil) to Dec. 2023 (€86.4 Mil) and declined from Dec. 2023 (€86.4 Mil) to Mar. 2024 (€70.6 Mil).

TG Therapeutics's annual Ending Cash Position declined from Dec. 2021 (€265.6 Mil) to Dec. 2022 (€97.8 Mil) and declined from Dec. 2022 (€97.8 Mil) to Dec. 2023 (€86.4 Mil).

TG Therapeutics Ending Cash Position Historical Data

The historical data trend for TG Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Ending Cash Position Chart

TG Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 102.50 455.96 265.63 97.78 86.40

TG Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.60 90.72 142.60 86.40 70.63

TG Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

TG Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=94.981+-8.583
=86.4

TG Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=86.681+-16.056
=70.6

TG Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics (STU:NKB2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (STU:NKB2) » Definitions » Ending Cash Position
Comparable Companies
KROS KYMR DYN VERA NTLA RCKT PTCT NAMS DNLI ARVN OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
TGTX:USA NKB2:Germany
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
Website
https://www.tgtherapeutics.com
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics (STU:NKB2) Headlines

No Headlines